19 March 2026 Sydney, Australia

Nyrada's PROTECT-MI Phase IIa Trial To Commence

Highlights:

- Nyrada on track to commence site initiation visits for its PROTECT-MI Phase IIa trial in March 2026.
- First patient dosing expected in April 2026.
- Seven (7) hospitals have been selected as initial sites.
- Trial designed to assess safety and preliminary efficacy of Xolatryp® in treating myocardial ischemia reperfusion injury in patients suffering a heart attack.
- Investigational New Drug (IND) submission in preparation.

Nyrada Inc (ASX:NYR), a clinical stage drug discovery and development company focused on advancing treatments across a portfolio of indications through innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibition, provides an update on its Phase IIa clinical trial. The trial name is PROTECT-MI (**P**revention of **R**eperfusion Injury **O**utcomes **T**hrough **E**ffective **C**ardioprotection **T**argeting **M**yocardial **I**nfarction).

PROTECT-MI will assess Nyrada's lead drug candidate Xolatryp in addressing myocardial ischemia reperfusion injury in patients suffering a STEMI heart attack. A STEMI heart attack is a severe, life-threatening heart attack caused by the complete blockage of a major coronary artery, stopping blood flow to a portion of the heart muscle.

Currently, no therapies have been approved to specifically target cardiac ischemia–reperfusion injury, which plays a major role in causing long-term heart damage following an acute myocardial infarction. Xolatryp is designed to address this important treatment gap.

Enrolment of patients in the PROTECT-MI study will conclude once 100 evaluable patients are dosed. Evaluable patients are those who have received either Xolatryp or placebo (50 drug, 50 placebo) and have completed all assessments specified in the study protocol.

Hospitals confirmed as initial trial sites include:

- Sunshine Hospital and Northern Health Hospital in Victoria
- Nepean Hospital and Liverpool Hospital in New South Wales
- Royal Adelaide Hospital in South Australia
- Sir Charles Gairdner Hospital in Western Australia
- Royal Hobart Hospital in Tasmania

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

Drug manufacture under Good Manufacturing Process (GMP) has been completed and delivery to the central distribution depot is expected in last week of March 2026. The formal GMP documentation is expected to follow shortly thereafter, allowing for patient recruitment to commence in April 2026. Nyrada will update the market once the first patient has been dosed.

Nyrada will provide regular updates on participant recruitment and Safety Review Committee (SRC) assessments. As the study will remain blinded until completion, efficacy data will only be analysed once the study has concluded.

Nyrada has also commenced preparation of its Investigational New Drug (IND) application to submit to the US Food and Drug Administration (FDA).

Further information on Nyrada's Phase IIa clinical trial is available in the appendices.

-ENDS-

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

Appendix 1 – About Xolatryp® and Key References

Xolatryp, previously called NYR-BI03, is a small molecule therapy that inhibits calcium ion influx via TRPC 3/6/7 channels. By limiting pathological calcium entry, it helps protect mitochondrial function and reduces ischemia reperfusion injury associated with acute myocardial infarction (heart attack).

A Phase I clinical trial assessing the safety, tolerability, and pharmacokinetics has been completed, and a Phase IIa clinical trial focusing on safety and preliminary efficacy will commence in April 2026. This upcoming study will enrol patients who suffer a heart attack and undergo Percutaneous Coronary Intervention (PCI - angioplasty with stenting).

Program Links:

- PROTECT-MI website - https://www.protect-mi.com
- Phase IIa factsheet - https://bit.ly/4bcDlKj
- Phase I results - https://bit.ly/3Nt0GzH
- GLP study results - https://bit.ly/4d8VYkX
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg
- Preclinical traumatic brain injury study - https://bit.ly/40fhrRT
- Preclinical stroke study - https://bit.ly/4sygHmH

Appendix 2 - Key Details of Xolatryp® Phase IIa Clinical Trial

(Subject to Change)

Protocol Title (long)	A Randomised, Double-Blind, Placebo-Controlled, Study of Xolatryp in Patients presenting with STEMI undergoing primary PCI
Protocol Title (short)	A Study of Xolatryp in Patients presenting with STEMI undergoing PCI
Other Title	**P**revention of **R**eperfusion Injury **O**utcomes **T**hrough **E**ffective **C**ardioprotection **T**argeting **M**yocardial **I**nfarction (PROTECT-MI)
Study Description	A Phase IIa, prospective, randomised, double-blind, placebo-controlled, multi-centre study that will evaluate the safety, pharmacokinetics and exploratory efficacy of Xolatryp, in addition to standards of care, in ST-Elevation Myocardial Infarction (STEMI) patients with primary percutaneous coronary intervention (PCI) following 6 hours of continuous infusion.
Primary Objectives	• To evaluate the safety and tolerability of Xolatryp when delivered as an infusion in patients presenting with an acute STEMI undergoing primary PCI • To evaluate the cardiac related safety of Xolatryp when delivered as an infusion in STEMI patients undergoing primary PCI
Further Objectives including	• To determine the cardiac infarct size utilising cardiac MRI in participants with pre-PCI TIMI 0 or 1 flow in patients treated with Xolatryp compared patients treated with placebo • To determine the incidence of arrhythmias of interest in patients treated with Xolatryp compared patients treated with placebo • To determine the blood PK in patients treated with Xolatryp compared patients treated with placebo • To determine the relative difference in serum levels of Troponin I in patients treated with Xolatryp compared patients treated with placebo • To compare patient reported outcomes at Day 30 in patients treated with Xolatryp compared patients treated with placebo
Study Design	Double-blind, placebo-controlled, randomised, multi-centre.
Treatment Method	3 mg/kg as an intravenous infusion over 6-hours.
Number of Trial Subjects	100 evaluable patients (50 drug, 50 placebo)

Key Inclusion Criteria	• Informed consent • Male patients aged 40 to 75 years of age • Female patients aged 55 to 75 years of age, or women less than 55 years that have no possibility of being pregnant • Patient presents with first-time STEMI, scheduled to undergo primary PCI within 6 h of symptom onset • Confirmation of STEMI with ST-elevation at the J-point in two contiguous leads • Hemodynamically stable
Exclusion Criteria	• Prior major cardiac surgery • Known contraindication to CMR • History of clinically significant renal impairment • Body weight < 50 kg or > 120 kg • Pregnant females of childbearing potential or breastfeeding females • Any condition or significant clinical abnormality identified at the time of screening that, in the judgment of the Investigator or any sub-Investigator, would preclude safe completion of the study
Coordinating Principal Investigator	Professor William Chan MBBS (Hons), FRACP, FCSANZ, PhD
Contract Research Organisation	Accelagen Pty. Ltd. 785 Toorak Road Hawthorn East VIC 3123 Australia
ClinicalTrials.gov ID and Link	NCT07362446

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in both cardioprotection and neuroprotection, and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial is soon to commence. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.